Skip to main content

Table 3 Mean change from baseline (week 0) and endpoint (week 12) of primary outcome measures in three groups of patients (mean ± SD), mean difference between groups and effect size (ES, d Cohen , g Hedges ) for mean changes from baseline of groups vs placebo group (95% CI), http://www.psychometrica.de/effect_size.html#anova

From: Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study

Study outcomes Curamin Placebo Curamed Intergroup comparison, mean difference or difference in rank sum$ and p values
     Placebo vs Curamin Placebo vs Curamed
WOMAC osteoarthritis total Index 7.38 ± 10.02* 2.26 ± 10.39 6.34 ± 11.38 −5.12 −4.08
    −24.84 $ −17.18 $
ES 0.50   0.37 P< 0.05* P> 0.05
WOMAC joint pain index 2.02 ± 2.93* 0.69 ± 2.70 1.86 ± 2.95 −1.32 −1.167
    P< 0.05* P> 0.05
ES 0.47   0.41   
WOMAC morning stiffness index 0.46 ± 1.35 0.14 ± 1.58 0.40 ± 1.54 −12.43 $ −9.12 $
    P> 0.05 P> 0.05
ES 0.22   0.17   
WOMAC limitation of physical function index 4.61 ± 6.66 1.34 ± 7.01 3.83 ± 7.56 −3.27 −2.49
    P> 0.05 P> 0.05
ES 0.48   0.34   
Chair Stand Test Score 1.74 ± 2.18* 0.44 ± 2.91 1.87 ± 2.41** 1.30 1.44
    P< 0.05* P < 0.01**
ES 0.51   0.53   
Fast Paced Walk Test Speed, m/s. 0.10 ± 0.18** 0.01 ± 0.22 0.08 ± 0.05* 0.12 0.10
    P< 0.01** P< 0.05*
ES 0.45   0.44   
Time up and go test, sec. 1.56 ± 2.04** 0.17 ± 0.84 0.78 ± 1.98 −1.39 −0.59
    P< 0.01** P> 0.05
ES 0.89   0.40   
Stair Climb Test, sec. 2.03 ± 3.60** 0.22 ± 2.84 1.66 ± 2.37 −1.82 −0.95
    P< 0.01** P> 0.05
ES 0.56   0.55   
Blood test 1: ESR −2.75 ± 0.77 −4.98 ± 0.85 −4.12 ± 0.88 16.63$
p > 0.05
−7.09$
p > 0.05
Blood test 2: CRP −0.787 ± 0.33 −1.376 ± 0.31 −1.274 ± 0.35 18.28$
p > 0.05
−8.67$
p > 0.05
  1. *p < 0.05, ** - p < 0.01 vs placebo
  2. $ - Non-parametric Kruskal-Wallis test with post Dunn's Multiple Comparison Test
  3. The overall change from baseline in Curamin, Curamed the placebo group. It was estimated as the effect size (the standard mean difference between baseline and endpoint) and this was compared with the obtained from placebo group control. An increase in all domains represents improvement in symptoms